Provexis (PXS) Competitors GBX 0.50 +0.05 (+10.44%) As of 03/28/2025 12:16 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock PXS vs. ALK, CLCO, ICON, PAA, GEL, MMP, AAL, CCL, SAVE, and GNKShould you be buying Provexis stock or one of its competitors? The main competitors of Provexis include Alkemy Capital Investments (ALK), CloudCoCo Group (CLCO), Iconic Labs (ICON), 22532 (PAA.L) (PAA), Greka Engineering & Technology (GEL), Marwyn Management Partners (MMP), Anglo American (AAL), Carnival Co. & (CCL), Savannah Energy (SAVE), and Greene King (GNK). These companies are all part of the "transportation" industry. Provexis vs. Alkemy Capital Investments CloudCoCo Group Iconic Labs 22532 (PAA.L) Greka Engineering & Technology Marwyn Management Partners Anglo American Carnival Co. & Savannah Energy Greene King Alkemy Capital Investments (LON:ALK) and Provexis (LON:PXS) are both small-cap financial services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Is ALK or PXS more profitable? Alkemy Capital Investments has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Alkemy Capital Investments' return on equity of 181.08% beat Provexis' return on equity.Company Net Margins Return on Equity Return on Assets Alkemy Capital InvestmentsN/A 181.08% -258.00% Provexis -73.10%-68.68%-56.14% Does the media favor ALK or PXS? In the previous week, Alkemy Capital Investments' average media sentiment score of 0.00 equaled Provexis'average media sentiment score. Company Overall Sentiment Alkemy Capital Investments Neutral Provexis Neutral Does the MarketBeat Community prefer ALK or PXS? Alkemy Capital Investments received 92 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 76.88% of users gave Alkemy Capital Investments an outperform vote while only 64.21% of users gave Provexis an outperform vote. CompanyUnderperformOutperformAlkemy Capital InvestmentsOutperform Votes15376.88% Underperform Votes4623.12% ProvexisOutperform Votes6164.21% Underperform Votes3435.79% Do institutionals and insiders have more ownership in ALK or PXS? 1.5% of Alkemy Capital Investments shares are owned by institutional investors. Comparatively, 7.9% of Provexis shares are owned by institutional investors. 43.7% of Alkemy Capital Investments shares are owned by company insiders. Comparatively, 21.6% of Provexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, ALK or PXS? Provexis has higher revenue and earnings than Alkemy Capital Investments. Provexis is trading at a lower price-to-earnings ratio than Alkemy Capital Investments, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkemy Capital InvestmentsN/AN/A-£1.29M-£14.59-9.06Provexis£846.98K13.77-£619.15K-£0.03-18.84 Which has more risk and volatility, ALK or PXS? Alkemy Capital Investments has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Provexis has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. SummaryAlkemy Capital Investments beats Provexis on 7 of the 12 factors compared between the two stocks. Remove Ads Get Provexis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PXS vs. The Competition Export to ExcelMetricProvexisDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£11.66M£2.27B£5.63B£2.61BDividend Yield5.06%2.92%5.33%4.82%P/E Ratio-18.844.2823.55141.21Price / Sales13.77575.41388.19284,066.48Price / CashN/A10.2538.1728.14Price / Book57.946.556.894.64Net Income-£619,153.31£20.70B£3.20B£5.83B7 Day Performance9.71%-2.72%-3.06%1.43%1 Month Performance-4.42%-2.95%1.51%7.39%1 Year Performance-20.48%92.64%9.37%32.92% Provexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PXSProvexisN/AGBX 0.50+10.4%N/A-20.5%£11.66M£846,984.38-18.844Gap UpALKAlkemy Capital InvestmentsN/AGBX 143.30-4.8%N/A+60.2%£12.63MN/A-9.8225,500Gap UpCLCOCloudCoCo GroupN/AGBX 0.15-3.2%N/A-79.2%£1.08M£27.84M-0.51125ICONIconic LabsN/AN/AN/AN/A£586,000.00£600,855.00-15.003Gap UpHigh Trading VolumePAA22532 (PAA.L)N/AN/AN/AN/A£0.00N/A0.004,100Gap UpHigh Trading VolumeGELGreka Engineering & TechnologyN/AN/AN/AN/A£0.00N/A0.002,110MMPMarwyn Management PartnersN/AN/AN/AN/A£0.00N/A0.001,660AALAnglo American1.1935 of 5 starsGBX 2,326.50-1.7%GBX 2,698.33+16.0%+14.9%£35.38B£36.94B-21.42129,700CCLCarnival Co. &N/AGBX 1,450.50+0.7%N/A+18.2%£26.21B£32.78B13.1540,000News CoverageSAVESavannah EnergyN/AGBX 7.80-3.1%N/AN/A£10.24B£18.46B-5.0611,100News CoverageGap UpGNKGreene KingN/AN/AN/AN/A£2.63B£2.22B21.941,010High Trading Volume Remove Ads Related Companies and Tools Related Companies Alkemy Capital Investments Alternatives CloudCoCo Group Alternatives Iconic Labs Alternatives 22532 (PAA.L) Alternatives Greka Engineering & Technology Alternatives Marwyn Management Partners Alternatives Anglo American Alternatives Carnival Co. & Alternatives Savannah Energy Alternatives Greene King Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PXS) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provexis plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Provexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
